News

Apeptico completes €3.4m financing round
Enlarge image

BusinessAustriaGermanySwitzerland

Apeptico completes €3.4m financing round

18.05.2012 - Austrian peptide drug developer Apeptico F&E GmbH has secured €3.4m financing.

Vienna – The Apeptico equity financing combined existing and new private and institutional investors, as well as a research grant from the Austrian Research Promotion Agency (FFG). Institutional and private investors contributed a total of €2m to the Series C financing – among them BioScience Venture Group, V+ GmbH & Co Fonds 2 KG, V+ GmbH & Co Fonds 3 KG, and business angels from Germany, Switzerland and the USA. At the end of 2011, Apeptico had already secured a research grant of €1.4m from the Austrian Research Promotion Agency FFG. 

Dr. Bernhard Fischer, CEO of Apeptico, commented: “This round C financing enables us to continue the clinical development of our lead peptide AP301. AP301 will be assessed in a “proof of concept” study in intensive care patients to investigate the clinical effect of repetitive orally inhaled doses of AP301 on alveolar liquid clearance in acute lung injury.“ 

AP301 is a patented (AT_507_953), water soluble, synthetic cyclic peptide in clinical development that mimics the lectin-like domain of the human tumour necrosis factor alpha (TNFalpha). It can be administered into the lung by instillation or by oral inhalation. AP301 was originally designed for the treatment of acute lung injury and acute respiratory distress syndrome. Additional research demonstrated that AP301 has additional significant potential in related clinical indications, such as prevention and treatment of pulmonary permeability oedema, prevention of progression of acute hypoxemic respiratory failure due to bacterial/viral pneumonia and prevention of ischemia reperfusion injury. 

http://www.european-biotechnology-news.com/news/news/2012-02/apeptico-completes-eur34m-financing-round.html

BusinessSwitzerland

03.07.2015 Biotech giant Biogen is investing CHF 1bn in a new pharmaceutical production plant in the Swiss town of Luterbach. Noted as one of the world’s oldest biotech firms, the new plant will create up to 400 jobs.

Personalised MedicineNetherlandsBelgiumSpain

02.07.2015 Dutch biotech Amarna and Austrian Biomarker research centre CBmed have joined forces to develop several immunotherapies, including therapies against cancer and diabetes type 2. The joint venture will develop Amarna’s next generation viral vector platform.

M&ASwitzerland

30.06.2015 Pharma giant Novartis has bumped up its neuroscience portfolio with the recent purchase of Australian biotech Spinifex for a US$200m upfront payment plus US$500 in milestone payments. The acquisition is centred on Spinifex’ mid-stage pain drug EMA401.

Personalised MedicineGermany

25.06.2015 German immunotherapy expert BioNTech AG has partnered up with Europe’s largest engineering company Siemens to construct a manufacturing site for BioNTech’s personalised cancer vaccine.

Bioelectronic researchSweden

24.06.2015 Swedish scientists have created artificial neurons that are capable of mimicking the function of human nerve cells. The researchers hope that, once minituarised, they may one day be used to restore disturbed neural function.

FinancingLuxembourgItalySwitzerland

23.06.2015 Cosmo Pharmaceuticals is floating its majority-owned subsidiary Cassiopea at the Swiss Stock Exchange, with the aim to raise between CHF150m and CHF200m.

EventEUGermany

22.06.2015 For the 31st time, the ACHEMA has drawn the global chemical engineering and the process industry to Frankfurt. Although still overshadowed by petrol, the biobased economy is getting ready to step out into the limelight.

EventEU

17.06.2015 At the BIO convention in Philadelphia, the biotech industry celebrates new gene and cell therapies, and hails its unlikely superheroes.

ResearchUKSwitzerland

16.06.2015 Northern Ireland’s biopharma Almac Discovery is partnering up with Roche subsidiary Genentech in a two-year joint research programme to discover and develop cancer treatments.

M&ANorwayFinlandSweden

12.06.2015 The high-potential cancer immunotherapy market is fiercely fought, and small companies have trouble making their mark. Nordic companies Targovax and Oncos have joined forces to create a Nordic immuno-oncology champion named Polaris.

Events

All Events

Current issue

All issues

Product of the week

Products

Stock list

All quotes

TOP

  • BAVARIAN NORDIC (D)44.62 EUR12.34%
  • MOLOGEN (D)5.20 EUR7.00%
  • BRITISH TECHNOLOGY GROUP (UK)686.00 GBP6.94%

FLOP

  • CYTOS (CH)0.50 CHF-9.09%
  • NOVACYT (F)4.99 EUR-6.90%
  • EPIGENOMICS (D)5.12 EUR-5.19%

TOP

  • DBV Technologies (F)54.26 EUR26.8%
  • VERONA PHARMA (UK)5.10 GBP17.2%
  • MEDIGENE (D)9.72 EUR16.0%

FLOP

  • CHRONTECH PHARMA (S)0.01 SEK-50.0%
  • TRANSGENE (F)3.80 EUR-26.9%
  • NORDIC NANOVECTOR (N)25.50 NOK-25.9%

TOP

  • ADOCIA (F)66.29 EUR388.1%
  • 4SC (D)4.90 EUR375.7%
  • VERONA PHARMA (UK)5.10 GBP314.6%

FLOP

  • CHRONTECH PHARMA (S)0.01 SEK-87.5%
  • ACTIVE BIOTECH (S)9.00 SEK-70.1%
  • NEOVACS (F)1.14 EUR-69.1%

No liability assumed, Date: 02.07.2015